Protein kinases are involved in the regulation of a broad range of cellular processes and are shown to have intimate relationships with the pathogenesis of many human diseases. Accordingly, kinase inhibitors have emerged both as indispensible tools for elucidation of the biological functions of kinases and as therapeutic agents for molecular-targeted therapy (Dar and Shokat, 2010) . In fact, based on the promise of drugs such as Gleevec/ imatinib, which neutralizes BCR-Abl for the treatment of chronic myelogenous leukemia, and PLX-4720, which targets the V600E mutant of B-Raf that occurs frequently in melanoma, there continues to be intense interest in the discovery of new kinase inhibitors. Despite some successes, the development of novel inhibitors and the identification of their bonafide cellular targets remain major challenges. A major obstacle relates to the shared architecture and catalytic mechanism for the 500 or so protein kinases that are encoded within the human genome. In this respect, many inhibitors that are currently available are directed against the catalytic or ATP site of kinases, raising the prospect of offtarget interactions with the many other kinases or other ATP-binding proteins that are present in cells. Accordingly, the design of selective kinase inhibitors typically requires detailed knowledge of the kinase target, including structural information and understanding of its regulation, as well as information regarding its oligomerization state and binding partner interactions (Dar and Shokat, 2010 ). An additional complication is highlighted by the recent, somewhat paradoxical observations that, in some instances, ATP-competitive kinase inhibitors can act as activators of the pathways that they were intended to inhibit. This is the case for the Raf kinase inhibitors (PLX4720, GDC-0879) that do effectively inhibit Raf signaling in cells expressing B-V600E Raf mutants (Hatzivassiliou et al., 2010; Poulikakos et al., 2010) . By comparison, in cells expressing wildtype B-Raf through a mechanism that involves inhibitor-induced dimerization between B-Raf and C-Raf (Raf-1), these inhibitors actually ''prime'' the activation of these complexes, leading to enhanced ERK/MAPK signaling in cells. Similar observations have been made with Akt and other AGC family kinases (Frye and Johnson, 2009 ). Overall, these findings demonstrate that kinase inhibitors can act in a cell context-dependent manner.
Over the past decade, many powerful technologies have been developed to characterize kinase inhibitor selectivity and identify kinase inhibitor targets. These approaches have involved the immobilization of kinase inhibitors or ATP onto solid supports to enable the affinity capture of kinases. For example, in the studies described by Karaman et al. (2008) , competition experiments performed with selected kinase inhibitors defined the relative binding affinities and specific kinase interaction profiles for these inhibitors. While these studies revealed considerable detail regarding the selectivity and specificity of ATPcompetitive kinase inhibitors (including dasatinib, lapatinib, and imatinib), these studies were highly dependent on the use of recombinant expressed kinase domains. By comparison, other approaches have involved screening for interactions with endogenous kinases using immobilized selective or pan kinase inhibitors (kinobeads) and quantitative mass spectrometry (Godl et al., 2003; Bantscheff et al., 2007; Sharma et al., 2009 ). This highly effective approach has provided considerable insight into the effects of inhibitors on the kinome of multiple disease models. A complementary method (KiNativ) employs highly reactive biotinlyated acyl phosphate derivatives of ATP and ADP as an affinity tagging approach to capture large numbers of native kinases from cells (Patricelli et al., 2007) .
In the new study by Patricelli et al. (2011) , the utility of the KiNativ approach has been extended to enable evaluation of the functionally relevant properties of kinase inhibitors on native kinases. In short, the authors developed a targeted mass spectrometry approach to interrogate the acyl phosphate-tagged kinome from cell lysates. Using a list of selected peptide kinase fragment ions and linear ion trap mass spectrometry, the authors report enhanced detection and quantification of more than 150 probe-labeled kinases from a chosen proteome. Thus, these studies represent one of the most comprehensive, direct analyses of ATPbinding sites of the native kinome performed to date. Furthermore, by performing the acylation reactions in the presence of kinase inhibitors, it was possible to obtain apparent binding constants for inhibitors with specific kinases.
Of significance in this study, the authors provide evidence that the response to kinase inhibitors depends on both the cellular context and the native properties of the endogenous kinase. This is most clearly demonstrated with epidermal growth factor receptor (EGFR), mitogen-activated protein kinase kinase 5 (MAP2K5), and Raf kinases. For EGFR, the authors show that the potency of erlotinib was highly dependent on the context of the receptor (i.e., intact versus
